Abstract
Colon cancer (CC) is one of the leading causes of mortality worldwide, leading to the search for effective therapies. In this context, immunotherapy is emerging as a promising strategy for CC patients. However, treatment response can vary widely among patients, with a significant proportion failing to respond adequately or developing serious adverse events. Therefore, the identification o…